Source: The Pharma Letter

Lodo Therapeutics: Lodo Therapeutics acquires Hibiskus BioPharma

New York, USA-based biotechnology firm Lodo Therapeutics announced today that it has completed the acquisition...

Read full article »
Lodo Therapeutics's Competitors | Lodo Therapeutics's News | Lodo Therapeutics's Financials
Stay up-to-date with the latest news on Lodo Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
100-250
Dale R. Pfost's photo - Chairman & CEO of Lodo Therapeutics

Chairman & CEO

Dale R. Pfost

CEO Approval Rating

89/100

Read more
Stay up-to-date with the latest news on Lodo Therapeutics